Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
EDOXABAN vs HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
60 mg orally once daily
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Category C
Category A/B
Anticoagulant
Anticoagulant